FTCD and hepatocellular carcinoma: Studies have shown an increase in UCK2 (31), HMMR (32), CABYR (33), and MAGEA6 (34) expression, and a significant decrease in CFHR3 (35), FTCD (36), and PARGC1A (37) expression in patients with HCC.